

# Marina B Klein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862639/publications.pdf>

Version: 2024-02-01

245  
papers

11,350  
citations

32410

55  
h-index

40945

97  
g-index

250  
all docs

250  
docs citations

250  
times ranked

13334  
citing authors

#	ARTICLE	IF	CITATIONS
1	Semiparametric Bayesian inference for optimal dynamic treatment regimes via dynamic marginal structural models. <i>Biostatistics</i> , 2023, 24, 708-727.	0.9	3
2	Tobacco smoking and HIV-related immunologic and virologic response among individuals of the Canadian HIV Observational Cohort (CANOC). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 982-991.	0.6	5
3	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	0.9	3
4	Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 277-279.	3.7	2
5	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>Cmaj</i> , 2022, 194, E242-E251.	0.9	103
6	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV-HCV co-infected population in Canada. <i>Antiviral Therapy</i> , 2022, 27, 135965352110676.	0.6	0
7	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 396-404.	0.9	1
8	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. <i>International Journal of Drug Policy</i> , 2022, 103, 103627.	1.6	6
9	Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV. <i>PLoS ONE</i> , 2022, 17, e0268521.	1.1	1
10	Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV. <i>International Journal of STD and AIDS</i> , 2022, 33, 847-855.	0.5	3
11	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2021, 73, e2234-e2242.	2.9	59
12	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. <i>Clinical Infectious Diseases</i> , 2021, 73, 468-477.	2.9	11
13	Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montreal: results from three cross-sectional studies (2005, 2009, 2018). <i>Sexually Transmitted Infections</i> , 2021, 97, 290-296.	0.8	7
14	Increased CD4:CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 729-737.	1.3	8
15	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
16	Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-7.	0.6	4
17	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021, 16, e0249836.	1.1	2
18	Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. <i>International Journal of Drug Policy</i> , 2021, 96, 103247.	1.6	43

#	ARTICLE	IF	CITATIONS
19	Risk of HCC With Hepatitis B Viremia Among HIV/HBV Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	3.6	26
20	Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. <i>International Journal of Drug Policy</i> , 2021, 96, 103343.	1.6	5
21	Clinical and demographic predictors of antiretroviral efficacy in HIV-HBV co-infected patients. <i>Jammi</i> , 2021, 6, 137-148.	0.3	0
22	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	5.8	67
23	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021, 224, 657-666.	1.9	3
24	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1131-1138.	2.9	26
25	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 363-371.	2.9	31
26	Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , 2020, 27, 205-220.	1.0	17
27	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
28	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	2.9	11
29	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.	1.0	25
30	Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 230-234.	0.9	7
31	Comparing direct acting antivirals for hepatitis C using observational data – Why and how?. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00650.	1.1	4
32	A randomized pilot study assessing the acceptability of rapid point-of-care hepatitis C virus (HCV) testing among male inmates in Montreal, Canada. <i>International Journal of Drug Policy</i> , 2020, 85, 102921.	1.6	16
33	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. <i>Vaccine</i> , 2020, 38, 3073-3078.	1.7	3
34	The Mediating Role of Depressive Symptoms in the Association Between Food Insecurity and HIV Related Health Outcomes Among HIV-HCV Co-Infected People. <i>AIDS and Behavior</i> , 2020, 24, 2188-2194.	1.4	1
35	Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 108-115.	1.0	3
36	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.	1.9	12

#	ARTICLE	IF	CITATIONS
37	The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019, 68, 788-794.	2.9	32
38	Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV/HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	5
39	Hepatitis C virus elimination: time for disruptive innovation. <i>Journal of the International AIDS Society</i> , 2019, 22, e25360.	1.2	8
40	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019, 188, 2097-2109.	1.6	32
41	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028 study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. <i>BMJ Open</i> , 2019, 9, e024793.	0.8	31
42	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	2.1	94
43	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 697-704.	0.5	7
44	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , 2019, 39, 2244-2260.	1.9	36
45	Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 204-213.	1.5	27
46	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV Coinfected Patients in Clinical Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz055.	0.4	10
47	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	2.1	46
48	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	0.6	2
49	Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada. <i>BMC Infectious Diseases</i> , 2019, 19, 982.	1.3	9
50	Delayed linkage to HIV care among asylum seekers in Quebec, Canada. <i>BMC Public Health</i> , 2019, 19, 1683.	1.2	12
51	The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E674-E679.	1.1	14
52	Trends in cause-specific mortality in HIV/hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , 2019, 33, 1013-1022.	1.0	23
53	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.	2.9	14
54	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019, 65, 41-49.	1.6	16

#	ARTICLE	IF	CITATIONS
55	Evaluating the impact of health policies: using a difference-in-differences approach. <i>International Journal of Public Health</i> , 2019, 64, 637-642.	1.0	21
56	Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators. <i>American Journal of Epidemiology</i> , 2019, 188, 1181-1191.	1.6	7
57	Determinants of Liver Complications Among HIV/Hepatitis B Virus Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	0.9	14
58	Use of Smoking Cessation Aids in a Convenience Sample of PLHIV in a Canadian Tertiary Care Clinic. <i>Open AIDS Journal</i> , 2019, 13, 1-6.	0.1	0
59	The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low to high income settings. <i>Journal of the International AIDS Society</i> , 2018, 21, e25073.	1.2	1
60	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1230-1238.	2.9	131
61	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , 2018, 21, e25051.	1.2	40
62	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , 2018, 32, 751-759.	1.0	9
63	Association between depressive symptoms, CD4 count and HIV viral suppression among HIV-HCV co-infected people. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 643-649.	0.6	14
64	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 62-72.	0.9	43
65	Injection drug use, food insecurity, and HIV-HCV co-infection: a longitudinal cohort analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1322-1328.	0.6	9
66	Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. <i>International Journal of Drug Policy</i> , 2018, 57, 95-103.	1.6	50
67	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. <i>Drug and Alcohol Dependence</i> , 2018, 185, 374-380.	1.6	6
68	Segmented generalized mixed effect models to evaluate health outcomes. <i>International Journal of Public Health</i> , 2018, 63, 547-551.	1.0	18
69	Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living With HIV in Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 144-153.	0.9	52
70	Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. <i>Canadian Liver Journal</i> , 2018, 1, 231-239.	0.3	9
71	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. <i>Journal of the International AIDS Society</i> , 2018, 21, e25197.	1.2	18
72	Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression. <i>Aids</i> , 2018, 32, 1323-1332.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United States)</i> , 2018, 97, 1-6.	0.4	22
74	Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging. <i>PLoS ONE</i> , 2018, 13, e0195148.	1.1	6
75	Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study. <i>AIDS Research and Treatment</i> , 2018, 2018, 1-6.	0.3	2
76	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society's Lancet Commission. <i>Lancet</i> , 2018, 392, 312-358.	6.3	230
77	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1507-1514.	1.0	26
78	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , 2018, 190, E677-E687.	0.9	93
79	Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018, 13, e0191985.	1.1	33
80	Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. <i>AIDS and Behavior</i> , 2017, 21, 792-802.	1.4	29
81	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 801-808.	1.8	70
82	Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?. <i>Journal of the International AIDS Society</i> , 2017, 20, 22146.	1.2	126
83	Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Women's Health Issues</i> , 2017, 27, 721-730.	0.9	56
84	The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV. <i>Journal of Infectious Diseases</i> , 2017, 216, 447-456.	1.9	16
85	Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis. <i>AIDS and Behavior</i> , 2017, 21, 3496-3505.	1.4	5
86	Impact of Food Insecurity on Depressive Symptoms Among HIV-HCV Co-infected People. <i>AIDS and Behavior</i> , 2017, 21, 3464-3472.	1.4	6
87	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	2.9	67
88	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 80.	1.3	6
89	A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. <i>BMC Infectious Diseases</i> , 2017, 17, 140.	1.3	31
90	Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2017, 17, 246.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. BMC Infectious Diseases, 2017, 17, 266.	1.3	7
92	Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. Hepatology, Medicine and Policy, 2017, 2, 8.	1.7	6
93	Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. AIDS and Behavior, 2017, 21, 754-765.	1.4	73
94	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clinical Infectious Diseases, 2017, 64, 1154-1162.	2.9	64
95	Disparities in direct acting antivirals uptake in HIV-hepatitis C coinfected populations in Canada. Journal of the International AIDS Society, 2017, 20, e25013.	1.2	52
96	Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. Canadian Journal of Public Health, 2017, 108, e169-e175.	1.1	6
97	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. PLoS ONE, 2017, 12, e0176282.	1.1	6
98	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-34.	0.7	21
99	Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfecting patients. Aids, 2016, 30, 1403-1311.	1.0	6
100	Fibroblast growth factor 23: associations with antiretroviral therapy in patients coinfected with HIV and hepatitis C. HIV Medicine, 2016, 17, 373-379.	1.0	4
101	Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 254-262.	0.9	11
102	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open, 2016, 4, E605-E614.	1.1	74
103	Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec. Clinical Infectious Diseases, 2016, 63, 1439-1448.	2.9	6
104	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases, 2016, 63, ciw531.	2.9	60
105	Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. American Journal of Epidemiology, 2016, 184, 249-258.	1.6	14
106	Opioid use and risk of liver fibrosis in HIV/hepatitis C virus coinfected patients in Canada. HIV Medicine, 2016, 17, 36-45.	1.0	10
107	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine, 2016, 34, 4799-4806.	1.7	33
108	A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada. Antiviral Therapy, 2016, 22, 325-335.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 521-526.	1.5	24
110	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016, 30, 2635-2643.	1.0	78
111	Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 590.	1.3	36
112	A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 531-539.	0.9	12
113	Food insecurity and low CD4 count among HIV-infected people: a systematic review and meta-analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1577-1585.	0.6	46
114	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	2.9	48
115	Responder Interferon $\lambda$ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2016, 214, 80-86.	1.9	9
116	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016, 62, 919-926.	2.9	65
117	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C Coinfected Persons. <i>Clinical Infectious Diseases</i> , 2016, 62, 242-249.	2.9	8
118	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw050.	0.4	14
119	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 50-58.	0.5	231
120	On Bayesian Estimation of Marginal Structural Models. <i>Biometrics</i> , 2015, 71, 279-288.	0.8	29
121	Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 453.	1.3	0
122	Rejoinder "On Bayesian Estimation of Marginal Structural Models". <i>Biometrics</i> , 2015, 71, 299-301.	0.8	4
123	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 413-421.	0.9	67
124	Epidemiology of hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 297-302.	1.5	34
125	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015, 18, 20024.	1.2	22
126	Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection " The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. <i>PLoS ONE</i> , 2015, 10, e0129868.	1.1	5



#	ARTICLE	IF	CITATIONS
127	Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design. <i>AIDS Research and Treatment</i> , 2015, 2015, 1-11.	0.3	12
128	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015, 16, 100-110.	2.0	22
129	Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv015.	0.4	25
130	Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals. <i>International Journal of Molecular Sciences</i> , 2015, 16, 6496-6512.	1.8	5
131	Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. <i>JAMA Internal Medicine</i> , 2015, 175, 178.	2.6	71
132	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv109.	0.4	10
133	HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2015, 16, 24-31.	1.0	14
134	Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. <i>BMC Infectious Diseases</i> , 2015, 15, 274.	1.3	103
135	Incomplete Modeling of the Effect of Antiretroviral Therapy on the Risk of Cardiovascular Events. <i>Clinical Infectious Diseases</i> , 2015, 61, 1206-1207.	2.9	2
136	The Impact of Sparse Follow-up on Marginal Structural Models for Time-to-Event Data. <i>American Journal of Epidemiology</i> , 2015, 182, kwv152.	1.6	6
137	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	2.9	142
138	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0141715.	1.1	74
139	CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e101441.	1.1	13
140	Physicians' Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 23-30.	0.8	42
141	Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. <i>Journal of the International AIDS Society</i> , 2014, 17, 18944.	1.2	35
142	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 311-320.	0.7	8
143	Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial. <i>HIV Clinical Trials</i> , 2014, 15, 161-175.	2.0	8
144	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	2.9	65

#	ARTICLE	IF	CITATIONS
145	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.	1.1	16
146	Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation. <i>Biometrics</i> , 2014, 70, 144-152.	0.8	18
147	A marginal structural model for multiple-outcome survival data: assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort. <i>Statistics in Medicine</i> , 2014, 33, 1409-1425.	0.8	15
148	Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). <i>Aids</i> , 2014, 28, 1957-1965.	1.0	50
149	Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans. <i>Clinical Infectious Diseases</i> , 2014, 58, 719-727.	2.9	50
150	Impact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription among Treatment-Naive, HIV-Infected Patients in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 153-159.	0.6	6
151	Factors Associated with Late Initiation of Highly Active Antiretroviral Therapy among Young HIV-Positive Men and Women Aged 18 to 29 Years in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 56-62.	0.6	10
152	Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. <i>Drug and Alcohol Dependence</i> , 2014, 137, 121-128.	1.6	13
153	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	0.8	77
154	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1579-1587.	2.9	63
155	High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. <i>Journal of Clinical Immunology</i> , 2014, 34, 655-662.	2.0	6
156	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300.	1.6	22
157	Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus-Infected, and Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1449-1458.	2.9	77
158	Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients. <i>Annals of Internal Medicine</i> , 2014, 160, 369-379.	2.0	214
159	Virus subtype, ethnicity and CD4 decline in untreated HIV infection. <i>Future Virology</i> , 2014, 9, 337-340.	0.9	1
160	Significant differences in clinical outcomes between HIV-hepatitis C virus coinfecting individuals with and without injection drug use history. <i>Aids</i> , 2014, 28, 121-127.	1.0	14
161	Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV-HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2013, 18, 717-721.	0.6	10
162	HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. <i>HIV Medicine</i> , 2013, 14, 10-20.	1.0	38

#	ARTICLE	IF	CITATIONS
163	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	1.9	43
164	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	2.9	90
165	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfecting with HIV: a prospective cohort study. <i>CMAJ Open</i> , 2013, 1, E106-E114.	1.1	12
166	Reply to Mandorfer et al. <i>Clinical Infectious Diseases</i> , 2013, 56, 905-906.	2.9	0
167	Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV–Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 663-670.	2.9	62
168	Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1339-1342.	2.9	4
169	Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 356-362.	0.9	131
170	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 149-163.	0.9	188
171	Invasive Cervical Cancer Risk Among HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 405-413.	0.9	184
172	Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. <i>Aids</i> , 2013, 27, 2863-2872.	1.0	6
173	Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e77665.	1.1	67
174	Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83649.	1.1	39
175	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	1.1	1,111
176	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 217-238.	0.7	10
177	Hepatitis B Screening and Vaccination Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e78548.	1.1	47
178	Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis. <i>Journal of Infectious Diseases</i> , 2012, 205, 1230-1238.	1.9	103
179	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. <i>Clinical Infectious Diseases</i> , 2012, 54, 1026-1034.	2.9	453
180	Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2012, 54, 1798-1805.	2.9	18

#	ARTICLE	IF	CITATIONS
181	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1<sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	22
182	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012, 26, 1789-1794.	1.0	16
183	Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. <i>Sexually Transmitted Infections</i> , 2012, 88, 558-564.	0.8	146
184	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. <i>Annals of Internal Medicine</i> , 2012, 157, 325.	2.0	106
185	Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44611.	1.1	123
186	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1<sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	12
187	CD8+ T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins. <i>Gastroenterology</i> , 2011, 140, 2064-2073.	0.6	42
188	Management and Treatment of Hepatitis B Virus in Patients with Hiv Infection: A Practical Guide for Health Care Professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 88-96.	0.7	3
189	Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. <i>Aids</i> , 2011, 25, 777-786.	1.0	51
190	Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV&#x2014;hepatitis C virus co-infection. <i>Aids</i> , 2011, 25, 967-975.	1.0	31
191	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	0.6	16
192	Validity of diagnostic codes and liver&#x2014;related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 689-699.	0.9	123
193	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for Determination of HIV-1 Viral Loads in a Cohort of Canadian Patients with Diverse HIV Subtype Infections. <i>Journal of Clinical Microbiology</i> , 2011, 49, 118-124.	1.8	53
194	Cohort Profile: The Canadian Observational Cohort collaboration. <i>International Journal of Epidemiology</i> , 2011, 40, 25-32.	0.9	41
195	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	1.6	9
196	Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 38-46.	0.9	14
197	Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis. <i>Clinical Infectious Diseases</i> , 2011, 52, 154-155.	2.9	17
198	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33

#	ARTICLE	IF	CITATIONS
199	Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. PLoS ONE, 2011, 6, e17758.	1.1	38
200	Frequent hepatitis B virus rebound among HIV/hepatitis B virus-coinfected patients following antiretroviral therapy interruption. Aids, 2010, 24, 857-865.	1.0	59
201	A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 451-459.	0.9	40
202	Virologic and immunologic response to HAART, by age and regimen class. Aids, 2010, 24, 2469-2479.	1.0	92
203	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. Aids, 2010, 24, 2639-2644.	1.0	5
204	HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim $\beta$ /PD $\alpha$ 1 expression that correlate with liver disease progression. European Journal of Immunology, 2010, 40, 2493-2505.	1.6	87
205	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infectious Diseases, 2010, 10, 40.	1.3	14
206	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	0.7	73
207	Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. International Journal of Epidemiology, 2010, 39, 1162-1169.	0.9	91
208	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases, 2010, 50, 1512-1520.	2.9	187
209	Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 297-301.	1.9	25
210	Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV/HCV coinfection before and after antiretroviral therapy. Aids, 2010, 24, 1857-1865.	1.0	71
211	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per $\mu$ L in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
212	Tuberculosis Screening and Active Tuberculosis among HIV-Infected Persons in a Canadian Tertiary Care Centre. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 51-57.	0.7	12
213	Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts. PLoS ONE, 2009, 4, e4517.	1.1	46
214	Rapid Testing at Labor and Delivery to Prevent Mother-To-Child Hiv Transmission in Developing Settings: Issues and Challenges. Women's Health, 2009, 5, 55-62.	0.7	11
215	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases, 2009, 49, 1582-1590.	2.9	55
216	Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). Journal of the International AIDS Society, 2009, 12, 11-11.	1.2	65

#	ARTICLE	IF	CITATIONS
217	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	13.9	986
218	Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. <i>HIV Therapy</i> , 2009, 3, 189-207.	0.6	1
219	Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. <i>Aids</i> , 2009, 23, 731-737.	1.0	38
220	CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. <i>Contemporary Clinical Trials</i> , 2008, 29, 617-630.	0.8	9
221	<i>Mycobacterium haemophilum</i> Epididymal Abscess in a Renal Transplant Patient. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2459-2460.	1.8	17
222	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	2.9	53
223	Are we ready for home-based, self-testing for HIV?. <i>Future HIV Therapy</i> , 2008, 2, 515-520.	0.5	22
224	Impact of Round-the-Clock, Rapid Oral Fluid HIV Testing of Women in Labor in Rural India. <i>PLoS Medicine</i> , 2008, 5, e92.	3.9	58
225	A Review of Influenza Vaccine Immunogenicity and Efficacy in HIV-Infected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 419-423.	0.7	15
226	Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. <i>AIDS Reviews</i> , 2008, 10, 212-23.	0.5	61
227	Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 463-469.	0.9	58
228	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	0.9	176
229	Influenzavirus Infection Is a Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults, Despite Vaccination. <i>Clinical Infectious Diseases</i> , 2007, 45, 234-240.	2.9	79
230	Management and Treatment of Hepatitis C Virus in Patients with HIV and Hepatitis C Virus Coinfection: A Practical Guide for Health Care Professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007, 18, 293-303.	0.7	9
231	Peering at peer review revealed high degree of chance associated with funding of grant applications. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 842-848.	2.4	57
232	Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. <i>Journal of Medical Virology</i> , 2006, 78, 1158-1163.	2.5	20
233	Structured treatment interruptions in chronic HIV management: where next?. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 909-912.	2.0	1
234	Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 521-532.	2.0	23

#	ARTICLE	IF	CITATIONS
235	The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. <i>Aids</i> , 2004, 18, 1895-1904.	1.0	24
236	The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 365-372.	0.9	94
237	Didanosine, interferon-alfa and ribavirin. <i>Aids</i> , 2003, 17, 1001-1008.	1.0	18
238	Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. <i>Aids</i> , 2003, 17, 1001-8.	1.0	8
239	The Agent of Human Granulocytic Ehrlichiosis Induces the Production of Myelosuppressing Chemokines without Induction of Proinflammatory Cytokines. <i>Journal of Infectious Diseases</i> , 2000, 182, 200-205.	1.9	75
240	A cloned CD15 $\alpha$ -negative variant of HL60 cells is deficient in expression of FUT7 and does not adhere to cytokine $\alpha$ -stimulated endothelial cells. <i>European Journal of Haematology</i> , 1999, 63, 42-49.	1.1	11
241	Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand. <i>Journal of Clinical Investigation</i> , 1999, 103, 407-412.	3.9	89
242	Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers. <i>Canadian Liver Journal</i> , 0, , .	0.3	2
243	Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patients and treatment provider perceptions. <i>Canadian Liver Journal</i> , 0, , .	0.3	1
244	Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
245	Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1